S_nmry In order to describe renal involvement in aggressive non-Hodgkin's lymphomas (NHLs) and its prognostic significance, we reviewed the outcome of 48 patients with renal involvement treated with the LNH-84 or LNH-87 regimen. Histology was diffuse large cell in 29 (60%) patients; immmunoblastic, diffuse mixed cell and lymphoblastic in four each; follicular large cell, diffuse small cleaved cell and diffuse small non-cleaved cell in one each; and unclassified in four. Ann Arbor stage was IV in 44 patients, and IE or IIE in four. Tumour mass > 10 cm, performance status (ECOG scale) > 2 and increased LDH level were present in 69%, 20% and 76% of patients respectively. Fifteen patients (31%) had multiple intraparenchymal nodules, 14 (29%) had direct spread into the kidney from a perirenal mass, ten (21%) had a single intraparenchymal nodule and nine (19%) had diffuse infiltration. Twenty-one patients (43%) presented with bilateral lesions. Three patients (6%) presented with acute renal failure. Ten other patients (21%) had serum creatinine >120 zmoll-'. In 12 of these 13 patients renal function was restored with chemotherapy. Twenty-eight patients (57%) achieved complete remission. Estimated 4 year disease-free survival was 39%. Disease-free survival and actuarial survival at 4 years were estimated to be 58% respectively. Two renal parameters had adverse prognostic sig i for survival: renal hilum involvement (P = 0.02) and diffuse renal infiltration (P = 0.01). A Cox model identified only two independent prognostic factors for survival, namely performance status > 2 and tumour size > 10 cm. We conclude that alteration in renal function occurs in 27% of patients with renal involvement. Systemic chemotherapy improves renal function rapidly. Long-term outcome is similar to that expected in NHL patients presenting with the same prognostic factors.
In clinical studies, the prevalence of renal involvement in patients with non-Hodgkin's lymphoma (NHL) ranges from 2.4% to 14% (Richmond et al., 1962; Strauss et al., 1983; Geffen et al., 1985; Richards et al., 1990) . This low incidence contrasts with the high prevalence (nearly 50%) of renal involvement found at autopsy (Wentzell & Berkheise, 1955; Martinez-Maldonado & Ramirez de Arellano, 1966; Lalli, 1969; Kandel et al., 1987; Richards et al., 1990) . Until the introduction of computerised tomography (CT), renal involvement was often found late in the clinical course of NHL patients. Systematic CT increased the early detection of renal lymphomatous involvement.
Intensive combination chemotherapy regimens in patients with aggressive NHL have been associated with complete response and 5 year survival rates of 75% and 60% respectively (Coiffier et al., 1989) . Most NHLs with renal involvement are aggressive (Richards et al., 1990) . Previous reviews of renal lymphomas were retrospective studies that included patients who received various regimens (Geffen et al., 1985; Richards et al., 1990) . The results of intensive combination chemotherapy regimens in patients with renal lymphomatous involvement have not been specifically analysed. In addition, prognostic factors identified in aggressive malignant lymphomas have not yet been assessed in this group of patients. For these reasons, we evaluated the renal symptoms, the prognostic factors and the outcome in 48 patients with aggressive lymphoma and renal involvement who were enrolled in the LNH-84 or LNH-87 regimen.
included in the prospective multicentre LNH-84 and LNH-87 protocols for aggressive lymphomas. Treatment modalities, detailed data and results for the 737 LNH-84 patients have been described previously (Coiffier et al., 1989) . Renal involvement was found in 80 of the 2,727 patients (3%).
Eligibility criteria for this present study were: (i) histologically proven renal involvement or (ii) (Carbone et al., 1971 We applied two prognostic models to our patients: the LNH-84 prognostic index (Coiflier et al., 1991) and the international prognostic index (Shipp et al., 1992 (Coiffier et al., 1989 Thirty-four patients were included in the multicentre LNH-87 protocol (Bosly et al., 1993 (Armitage, 1971) . Survival curves were plotted according to the Kaplan-Meier method and compared with the log-rank test (ManteL 1966) . Initial renal characteristics identified by the univariate analysis were included in a proportional hazards regression analysis of survival with the stepwise selection (Cox, 1982) . These analyses were performed using the Statistical Application System (SAS) software (SAS Institute, Cary, NC, USA).
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The main initial characteristics of the 48 patients are shown in Table I (BUN) and creatinine levels at the end of the induction mgimen. Renal parameters associated with a high CR rate were (Table IV) normal perinephric space (P = 0.01), multiple nodular involvement of the kidney (P = 0.02) and normal kidney hilum (P = 0.02).
Two renal parameters had adverse prognostic significace for survival: renal hilum involvement (P = 0.02) and diffuse renal infiltration (P = 0.01). Only three other prognostic factors were indicators of long survivaL, namely performance status 0 or 1 (P = 0.001), normal LDH level (P = 0.02) and diffuse large-cell histological subtype (P = 0.03). A Our report demonstrates that a high complete response rate and 4 year estimated survival rate can be achieved in aggressive NHL with renal involvement with the LNH-84 or LNH-87 regimen.
Distribution of histological subtypes of patients with lymphomatous involvement of the kidney was not significantly different from that found in all patients enrolled in the LNH-84 protocol (Coiffier et al., 1989) . Our study excluded low-grade NHL. However, only 7% of NHLs with renal involvement are low-grade NHL (Glicklich et al., 1986; Richards et al., 1990) .
In 26 patients, renal involvement was diagnosed on CT scan only. Radiological criteria are sufficient to diagnose a renal lymphomatous involvement (Richards et al., 1990) . CT scan usually reveals a homogeneous mass that shares the density of soft tissues, with a minimal enhancement after injection (Heiken et al., 1983) . Incidences of renal involvement subtypes in our patients semed somewhat different from those of previous reports (Richmond et al., 1962; Jafri et al., 1982; Heiken et al., 1983) . However, these studies included only a small number of patients and the differences were not signifant. Multiple nodules was the most common type (33-43%), followed by single nodule (13-22%) and direct spread from prirenal mass (11-28%). Diffise infil--)n .55 27 14 13 NS tration was slightly more frequent (17%) in our study tha in others (6%). Indeed, we included diffuse unilateral involvement in the diffus infiltration, while other reports restricted this type of involvement only to bilateral infiltration (Heiken et al., 1983) . Perirenal space was involved in 38-61% of patients (Jafri et al., 1982; Heiken et al., 1983) and even more (95%) in a histological study (Hartman et al., 1982) . Lomboaortic lymph nodes were involved in 61-100% of patients (Richards et al., 1990; Jafri et al., 1982; Heiken et al., 1983) . Our study suggests an association between renal involvement and mediastinum or bone involvement. These findings have atready been reported (Perrone et al., 1986; Richards et al., 1990) .
Twenty-seven per cent of our patients, 25% of patients of Richards et al. (1990) and six out of nine patients of Geffen et al. (1985) had increased creatinine level (>120pmol 11).
We report three patients who presented with acute renal failure (ARF). All of them had diffuse bilateral infiltration. This association has been already described (Kanfer et al., 1976; Randolph et al., 1983; Glicklich et al., 1986; Koolen et al., 1988) . The ACVB regimen is an intensive chemotherapy regimen that includes no major nephrotoxic drugs, especially no methotrexate, in the induction phase. Thus, we believe that, based on our findings and the report of Geffen et al. (1985) (Flombaum, 1988) . Haematological toxicity in the 48 patients with renal involvement was similar to that in the 737 patients who received the LNH-84 protocol (Coiffier et al., 1989) . Furthermore, we found no influence of initial impairment of renal function on haematological toxicity. We found that treatment responses in kidneys and in other sites of disease were similar and simultaneous. Radiological disappearance was often rapid, within 1 week to 6 months (Randolph et al., 1983; Glicklich et al., 1986; Cadman et al., 1988; Koolen et al., 1988; Richards et al., 1990 ).
Few series have described the results of treatment in patients with aggressive lymphoma and renal involvement. Complete remission has already been reported in primary NHL (Betta et al., 1986) or in patients with acute renal failure (Randolph et al., 1983; Koolen et al., 1988) with a follow-up of more than 18 months. CR rate ranged from 44% to 69% in previous senres (Geffen et al., 1985; Richards et al., 1990) . CR persisted for more than 1 year in 38-54% of patients (Geffen et al., 1985; Richards et al., 1990) . Relapse has occurred in 22-50% of CR patients (Geffen et al., 1985; Richards et al., 1990) . Twenty-three per cent of patients died within 3-4 months after diagnosis, either from disease progression or from toxicity of the induction regimen (Geffen et al., 1985; Richards et al., 1990 ). The present report describes the results of intensive combination chemotherapy regimens in a large number of patients: The CR rate and the percentage of patients who died during the induction phase were estimated to be 57% and 27% respectively, and agree with previous findings. Four year disease-free survival and 4 year overall survival were estimated to be 58 ± 9 and 46 ± 7% respectively.
Among initial renal characteristics, only diffuse infiltration and hilus involvement had a poor prognostic value for survival in our series. In a previous report (Glicklich et al., 1986) , only one out of six patients with diffuse bilateral involvement (and ARF) was alive at 2 years despite a doxorubicin-containing regimen. However, multivariate analysis demonstrated that no renal characteristics retained independent prognostic value for survival. This analysis sug-gests that only tumoral mass > 1O cm (in kidney or elsewhere) and performance status > 2 had independent poor prognostic value for survival. Furthermore, we found a large predominance of high-risk or high-to intermediate-risk patients according to the prognostic index of the protocol or the international prognostic index. Ann Arbor stage IV (Kanfer et al., 1976; Randolph et al., 1983; Geffen et al., 1985; Glicklich et al., 1986; Richards et al., 1990 ) and other extranodal localisation (Richards et al., 1990) were nearly constant in previous reports, as in ours. Thus renal involvement affected staging rarely. Geffen et al. (1985) found at least one unfavourable prognostic factor in all patients, and three or more unfavourable prognostic factors in seven out of nine patients (Geffen et al., 1985) . Finally, our survival estimate agrees with that expected in a series of patients with aggressive NHL and similar distribution of prognostic index Shipp et al., 1993) .
In conclusion, renal involvement is rare and often asymptomatic. Indeed, it usually occurs in the setting of disseminated disease, with other unfavourable prognostic factors. Systemic chemotherapy improves renal function rapidly.
Responses to an intensive chemotherapy regimen are similar to those obtained in other patients with advanced-stage NHL with similar initial prognostic factors.
